LQVTDSGLYRCVIYHPP (LP17) TFA is a triggering receptor expressed on myeloid cells (TREM-1) inhibitory peptide. LQVTDSGLYRCVIYHPP TFA substantially alleviates ischemia-induced infarction and neuronal injury. LQVTDSGLYRCVIYHPP TFA can get access into brain and block TREM-1.
性状
Solid
IC50 & Target[1][2]
TREM-1
体外研究(In Vitro)
LQVTDSGLYRCVIYHPP (LP17) (1 or 10?μM; 24 h) substantially decreases mRNA levels of pro-inflammatory cytokines and chemokines after reoxygenation and remarkably attenuates extracellular protein levels of IL-1β and IL-18 in a microglia oxygen-glucose deprivation (OGD) model.LQVTDSGLYRCVIYHPP (LP17) (10 μM; 24 h) interacts with microglial SYK. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
LQVTDSGLYRCVIYHPP (LP17) (0.5 or 1 mg/kg; intranasal; daily for 3 days) alleviates ischemia-induced infarction and neuronal injury in mice. has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Sealed storage, away from moisture and lightPowder -80°C 2 years;-20°C 1 year
SequenceShortening
LQVTDSGLYRCVIYHPP
参考文献
[1]. Pengfei Xu, et al. Microglial TREM-1 receptor mediates neuroinflammatory injury via interaction with SYK in experimental ischemic stroke. Cell Death Dis. 2019 Jul 19;10(8):555.
溶解度数据
In Vitro: DMSO : ≥ 100 mg/mL (48.19 mM)H2O : < 0.1 mg/mL (ultrasonic;adjust pH to 3 with HCl) (insoluble)